Skip to content
DataLookout
Menu

NEMODENCT07926867

A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

To study the efficacy of Nemolizumab on pruritus in patients > 12yo with DEB after 4 weeks of treatment, in a multicentric, prospective, and open pilot study.
Timeframe: 4 weeks

Secondary (1)

To describe the evolution of the following efficacy and health outcomes measures after 24 weeks of treatment

Arms and interventions

Nemolizumab will be administered as a 60 mg loading dose (two 30 mg injections) at Day 0, followed bExperimental

Neolizumab

Drugs: Neolizumab

Sites

4 sites in 1 country